Bio-Works Technologies AB (publ) (NGM:BIOWKS)
Sweden
· Delayed Price · Currency is SEK 3.170
+0.370 (13.21%)
At close: Mar 6, 2026
Bio-Works Technologies AB Revenue
In the year 2025, Bio-Works Technologies AB had annual revenue of 63.11M SEK with 107.01% growth. Bio-Works Technologies AB had revenue of 24.03M in the quarter ending December 31, 2025, with 213.46% growth.
Revenue
63.11M
Revenue Growth
+107.01%
P/S Ratio
4.85
Revenue / Employee
2.43M
Employees
26
Market Cap
306.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.11M | 32.62M | 107.01% |
| Dec 31, 2024 | 30.49M | -13.41M | -30.55% |
| Dec 31, 2023 | 43.90M | 2.58M | 6.23% |
| Dec 31, 2022 | 41.32M | -15.04M | -26.68% |
| Dec 31, 2021 | 56.36M | 49.13M | 679.08% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elicera Therapeutics AB | 10.86M |
| Lipum AB | 1.93M |
| Mendus AB | -1.44M |
| Corline Biomedical AB | 8.59M |
| Oncopeptides AB | 71.12M |
| Intervacc AB | 20.09M |
| Xintela AB | 2.28M |
| Sprint Bioscience AB | 167.17M |